Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a strategic partnership with Germany’s BioNTech SE (NASDAQ: BNTX), a leading figure in the biopharmaceutical industry. This collaboration aims to leverage Triastek’s cutting-edge 3D drug printing capabilities to develop a breakthrough oral preparation designed to address currently unmet clinical needs.
As part of the agreement, BioNTech will make an initial payment of USD 10 million to Triastek, with a further commitment to invest a minimum of USD 1.2 billion in product development, regulatory filing, and commercialization milestones. Additionally, Triastek will receive tiered royalties based on future sales.
Triastek will apply its expertise in 3D drug printing technology to co-develop innovative oral formulations with BioNTech. The goal is to enhance the delivery of RNA drugs through the gastrointestinal mucosa, minimize the degradation of RNA drugs in the gastrointestinal tract, and ensure precise delivery of RNA drugs to the optimal absorption sites within the gastrointestinal tract.- Flcube.com
